ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has received an average rating of "Moderate Buy" from the six research firms that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $8.50.

ALXO has been the topic of a number of recent research reports. Jefferies Financial Group cut ALX Oncology from a "buy" rating to a "hold" rating and decreased their target price for the stock from $12.00 to $2.00 in a report on Thursday. Cantor Fitzgerald reiterated an "overweight" rating on shares of ALX Oncology in a research report on Wednesday, December 18th. Finally, HC Wainwright restated a "buy" rating and set a $25.00 price objective on shares of ALX Oncology in a report on Wednesday, December 18th.

Insider Transactions at ALX Oncology

In related news, Director Rekha Hemrajani purchased 30,000 shares of ALX Oncology stock in a transaction dated Monday, December 2nd. The stock was acquired at an average cost of $1.55 per share, with a total value of $46,500.00. Following the completion of the transaction, the director now directly owns 33,000 shares of the company's stock, valued at $51,150. This trade represents a 1,000.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 33.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP boosted its stake in shares of ALX Oncology by 423.0% during the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company's stock valued at $3,833,000 after buying an additional 514,133 shares during the period. Privium Fund Management B.V. purchased a new stake in shares of ALX Oncology during the second quarter worth $2,271,000. XTX Topco Ltd acquired a new stake in ALX Oncology during the third quarter valued at $578,000. Point72 Asset Management L.P. purchased a new position in ALX Oncology in the second quarter valued at about $1,834,000. Finally, Los Angeles Capital Management LLC purchased a new position in ALX Oncology in the third quarter valued at about $469,000. 97.97% of the stock is owned by hedge funds and other institutional investors.

ALX Oncology Price Performance

ALX Oncology stock traded up $0.25 during mid-day trading on Monday, hitting $1.87. The company's stock had a trading volume of 1,870,784 shares, compared to its average volume of 833,825. The stock has a market capitalization of $98.63 million, a P/E ratio of -0.63 and a beta of 1.04. ALX Oncology has a twelve month low of $1.19 and a twelve month high of $17.83. The stock's fifty day moving average price is $1.49 and its two-hundred day moving average price is $3.25. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.